The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Function, structure and therapeutic potential of complement C5a receptors
Open accessAbstract
Complement fragment (C)5a is a 74 residue pro‐inflammatory polypeptide produced during activation of the complement cascade of serum proteins in response to foreign surfaces such as microorganisms and tissue damaged by physical or chemical injury. C5a binds to at least two seven‐transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. C5aR is a classical G protein‐coupled receptor that signals through G α i and G α 16, whereas C5L2 does not appear to couple to G proteins and has no known signalling activity. Although C5a was first described as an anaphylatoxin and later as a leukocyte chemoattractant, the widespread expression of C5aR suggested more general functionality. Our understanding of the physiology of C5a has improved significantly in recent years through exploitation of receptor knockout and knockin mice, C5 and C5a antibodies, soluble recombinant C5a and C5a analogues and newly developed receptor antagonists. C5a is now also implicated in non‐immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis. Combined receptor mutagenesis, molecular modelling, structure‐activity relationship studies and species dependence for ligand potency on C5aR have been helpful for identifying ligand binding sites on the receptor and for defining mechanisms of receptor activation and inactivation. This review will highlight major developments in C5a receptor research that support C5aR as an important therapeutic target. The intriguing possibilities raised by the existence of a non‐signalling C5a receptor are also discussed. British Journal of Pharmacology (2007) 152, 429–448; doi:10.1038/sj.bjp.0707332; published online 2 July 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
G PROTEIN–COUPLED RECEPTOR KINASES
Pitcher, J. A., Freedman, N. J., & Lefkowitz, R. J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.653 · Cited by 1,361
Biology of the p21-Activated Kinases
Bokoch, G. M. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161742 · Cited by 1,089
Arthritis Critically Dependent on Innate Immune System Players
Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M. A., Boackle, S. A., Takahashi, K., Holers, V. M., Walport, M., Gerard, C., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00275-3 · Cited by 693
The chemotactic receptor for human C5a anaphylatoxin
Gerard, N. P., & Gerard, C. (1991) · Nature · doi:10.1038/349614a0 · Cited by 655
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318817 · Cited by 594
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18817 · Cited by 575
Hammerschmidt, D., Hudson, L., Weaver, L. J., Craddock, P., & Jacob, H. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91403-8 · Cited by 556
Medical Treatment of Osteoarthritis
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91263-8 · Cited by 554
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase
Bokisch, V. A., & Müller-Eberhard, H. J. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106462 · Cited by 517
Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M., & Salmon, J. E. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061022 · Cited by 508
Cited by
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
Modulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778
The role of the anaphylatoxins in health and disease
Klos, A., Tenner, A. J., Johswich, K.-O., Ager, R. R., Reis, E. S., & Köhl, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.027 · Cited by 730
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Complement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
Orally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Self-citationMicroglia and Inflammation in Alzheimers Disease
Mandrekar-Colucci, S., & Landreth, G. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012071 · Cited by 421
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Self-citationSalminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.001 · Cited by 346
The Staphylococcal Toxin Panton-Valentine Leukocidin Targets Human C5a Receptors
Spaan, A. N., Henry, T., van Rooijen, W. J. M., Perret, M., Badiou, C., Aerts, P. C., Kemmink, J., de Haas, C. J. C., van Kessel, K. P. M., Vandenesch, F., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.04.006 · Cited by 301
Complement, C1q, and C1q-Related Molecules Regulate Macrophage Polarization
Bohlson, S. S., O’Conner, S. D., Hulsebus, H. J., Ho, M.-M., & Fraser, D. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00402 · Cited by 297
Inhibiting the C5–C5a receptor axis
Woodruff, T. M., Nandakumar, K. S., & Tedesco, F. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.014 · Cited by 289
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Fonseca, M. I., Ager, R. R., Chu, S.-H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901005 · Cited by 268
Crosstalk pathways between Toll-like receptors and the complement system
Hajishengallis, G., & Lambris, J. D. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.01.002 · Cited by 275
Complement and the Regulation of T Cell Responses
West, E. E., Kolev, M., & Kemper, C. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053245 · Cited by 269
Klos, A., Wende, E., Wareham, K. J., & Monk, P. N. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005223 · Cited by 264
Self-citationSystemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Self-citationSpaan, A. N., Vrieling, M., Wallet, P., Badiou, C., Reyes-Robles, T., Ohneck, E. A., Benito, Y., de Haas, C. J. C., Day, C. J., Jennings, M. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6438 · Cited by 166
Complement as a regulator of adaptive immunity
Killick, J., Morisse, G., Sieger, D., & Astier, A. L. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0644-y · Cited by 129
“Although initially suggested that C5a bound to C5aR1 with less affinity than C5a [10], this was recently challenged [11].”
BackgroundIncreased peri‐ductal collagen micro‐organization may contribute to raised mammographic density
McConnell, J. C., O’Connell, O. V., Brennan, K., Weiping, L., Howe, M., Joseph, L., Knight, D., O’Cualain, R., Lim, Y., Leek, A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0664-2 · Cited by 110
Conroy, A., Serghides, L., Finney, C., Owino, S. O., Kumar, S., Gowda, D. C., Liles, W. C., Moore, J. M., & Kain, K. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004953 · Cited by 81
C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages
Li, X. X., Clark, R. J., & Woodruff, T. M. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000407 · Cited by 62
Kagawa, T. F., O'Connell, M. R., Mouat, P., Paoli, M., O'Toole, P. W., & Cooney, J. C. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.12.074 · Cited by 50
Kusakabe, J., Hata, K., Miyauchi, H., Tajima, T., Wang, Y., Tamaki, I., Kawasoe, J., Okamura, Y., Zhao, X., Okamoto, T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.001 · Cited by 18
Metadata
- Authors
- Monk, P. N., Scola, A., Madala, P., & Fairlie, D. P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-10
- Volume
- 152
- Issue
- 4
- Pages
- 429-448
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2053443014
- Cited by
- 404
- References
- 199
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.